Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

6.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
6.0K
Infectious Diseases and Their Occurrence01:28

Infectious Diseases and Their Occurrence

83
Infectious diseases appear in populations through various transmission patterns, influenced by pathogen characteristics, population immunity, environmental conditions, and social behavior. Understanding these patterns is essential for effective public health surveillance and intervention. These categories—sporadic, outbreak, epidemic, pandemic, and endemic—help frame the nature and scope of disease events.Sporadic diseases occur irregularly and infrequently, without a predictable...
83
Infection01:20

Infection

11.3K
When a pathogen enters the body and reproduces, it can cause an infection, damage body cells, and cause illness symptoms that eventually lead to disease. Therefore, its prevention requires breaking the chain of infection.
The chain begins with pathogens: bacteria, viruses, fungi, prions, or parasites such as protozoa helminths. These can be present on the skin as transient or resident flora, or they can be acquired from the environment. Identifying and treating the type of infection and...
11.3K
Principles of Disease Surveillance01:26

Principles of Disease Surveillance

850
Disease surveillance is the systematic collection, analysis, and interpretation of health data essential to the planning, implementation, and evaluation of public health practice. This process integrates data dissemination to entities responsible for preventing and controlling disease, injury, and disability. Surveillance systems provide crucial information for action, helping public health authorities make informed decisions to manage and prevent outbreaks, ensure public safety, optimize...
850
Defense Mechanism Against Infection01:26

Defense Mechanism Against Infection

9.5K
Natural flora, body system defenses, and inflammation are natural barriers of the body against infectious agents regardless of previous exposure. Normal floras of the human body refer to the microbial population that colonizes the skin and mucous membranes.
In addition, many body organ systems have unique defenses against infection. The skin is an intact, multilayered surface preventing invasion by microorganisms unless impaired. Mucous membranes lining the mouth, nose, and eyelids are barriers...
9.5K
Chemical Agents for Microbial Control01:27

Chemical Agents for Microbial Control

1.6K
Chemicals play important roles in controlling microbial growth by targeting microbial structures and functions as sanitizers, antiseptics, disinfectants, and sterilants.Alcohols are commonly used sanitizers, effectively disrupting lipid membranes, which compromises cell integrity. They are also used as antiseptics and disinfectants due to their rapid action and versatility.Phenols and their derivatives phenolics , known for denaturing proteins and disrupting cell membranes, are particularly...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utilizing PBPK Modeling to Evaluate the Potential of a Significant Drug-Drug Interaction Between Clopidogrel and Dasabuvir: A Scientific Perspective.

Clinical pharmacology and therapeutics·2017
Same author

Direct-acting antiviral drugs for the treatment of chronic hepatitis C virus infection: Interferon free is now.

Clinical pharmacology and therapeutics·2015
Same author

Justification of noninferiority margin: methodology considerations in an exposure-response analysis.

Clinical pharmacology and therapeutics·2015
Same author

Evaluation of various static in vitro-in vivo extrapolation models for risk assessment of the CYP3A inhibition potential of an investigational drug.

Clinical pharmacology and therapeutics·2013
Same author

Acceleration of drug development: a collaboration of many stakeholders.

Clinical pharmacology and therapeutics·2013
Same author

Achieving the promise of personalized medicine.

Clinical pharmacology and therapeutics·2012
Same journal

Symposium Report: Stakeholders' Perspectives on Phase 1 Trials in Japanese Prior to Multi-Regional Clinical Trials and Future Pathways.

Clinical pharmacology and therapeutics·2026
Same journal

Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

Clinical pharmacology and therapeutics·2026
Same journal

Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

Clinical pharmacology and therapeutics·2026
Same journal

Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

Clinical pharmacology and therapeutics·2026
Same journal

Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

Clinical pharmacology and therapeutics·2026
Same journal

Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

Clinical pharmacology and therapeutics·2026
See all related articles

Related Experiment Video

Updated: Apr 26, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K

Combining forces to combat infectious diseases.

K S Reynolds1

  • 1Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.

Clinical Pharmacology and Therapeutics
|July 25, 2014
PubMed
Summary
This summary is machine-generated.

Collaborations between industry, academia, and the public accelerate the development of new drugs. Strong science and clinical trial expertise are crucial for creating treatments for infectious diseases like resistant bacteria, hepatitis C virus (HCV), and HIV prevention.

More Related Videos

Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 3. Aerobiology
11:13

Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 3. Aerobiology

Published on: October 3, 2016

13.8K
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

7.3K

Related Experiment Videos

Last Updated: Apr 26, 2026

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method
07:51

High-throughput Identification of Synergistic Drug Combinations by the Overlap2 Method

Published on: May 21, 2018

11.5K
Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 3. Aerobiology
11:13

Safety Precautions and Operating Procedures in an ABSL-4 Laboratory: 3. Aerobiology

Published on: October 3, 2016

13.8K
High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity
09:09

High Throughput, Real-time, Dual-readout Testing of Intracellular Antimicrobial Activity and Eukaryotic Cell Cytotoxicity

Published on: November 16, 2016

7.3K

Area of Science:

  • Infectious disease research
  • Drug development and discovery
  • Public health initiatives

Background:

  • Infectious diseases pose significant public health threats, necessitating advanced therapeutic solutions.
  • Public attention on infectious diseases drives the need for accelerated drug development pipelines.

Discussion:

  • Multi-sectoral collaborations, including industry, academia, regulators, and the public, are vital for advancing drug development.
  • These partnerships must be built upon rigorous scientific principles and robust clinical trial expertise.

Key Insights:

  • Collaborative efforts are proving effective in developing novel treatments for drug-resistant bacterial infections.
  • Significant progress is being made in creating new therapies for hepatitis C virus (HCV) infection.
  • Advancements in drug development are also focusing on effective HIV prevention strategies.

Outlook:

  • Continued collaboration is expected to yield further breakthroughs in combating infectious diseases.
  • The integration of diverse expertise will enhance the speed and success of future drug development programs.
  • Public-private partnerships will remain essential for addressing emerging and persistent infectious disease challenges.